Overview of Upsarin C

Quick Facts

Property	Description
Active ingredient	Acetylsalicylic Acid (ASA) and Sodium Ascorbate
Form	Effervescent Tablets
Pharmacological class	NSAID and Vitamin Supplement (Combination)
Common use	Symptomatic Pain Relief and Fever Reduction
Origin	Synthetic (ASA) and Essential Vitamin (Ascorbic Acid)

Identity and Pharmacological Classification of Upsarin C

Upsarin C is a fixed-dose combination product intended for oral, systemic administration, chemically comprising a salicylate derivative and an essential vitamin supplement. The primary medicinal component, Acetylsalicylic Acid (ASA), is a synthetic compound belonging to the Nonsteroidal Anti-inflammatory Drug (NSAID) class, which is clinically recognized for its therapeutic effects. This specific product, often associated with the French manufacturer UPSA SAS, utilizes a rapid-dissolving Effervescent Tablets format, a distinctive characteristic that differentiates it from conventional solid ASA preparations. The medicine's identity is centered on these two distinct pharmacological groups: the analgesic and antipyretic effects of ASA, combined with the antioxidant properties of Ascorbic Acid.

Composition, Drug Form, and General Therapeutic Purpose

The formulation consists of Acetylsalicylic Acid and Sodium Ascorbate (a source of Ascorbic Acid), which functions as a redox cofactor and contributes to a buffered formulation. The Effervescent Tablets must be dissolved in water to create an oral solution prior to ingestion. The general therapeutic purpose of this combination is to provide efficient symptomatic treatment of common, non-specific ailments. The antipyretic effect of ASA helps reduce fever, while its analgesic effect provides effective pain relief. This established dual action is often employed to manage general discomfort, such as during the onset of flu-like conditions, by addressing both elevated temperature and physical aches.

Regulatory References

Aspirin: MedlinePlus Drug Information - NIH

What side effects are possible with Upsarin C?

Possible Side Effects and Safety Information

Upsarin C, a combination of Acetylsalicylic Acid (ASA) and Ascorbic Acid, has an officially documented safety profile structured around risks associated primarily with the NSAID component. The possible side effects are formally classified by frequency and grouped according to the body system affected, ensuring a clear regulatory description of the risk landscape.

Officially documented adverse reactions classified as common include gastrointestinal disorders such as heartburn, nausea, vomiting, and abdominal pain. Uncommon effects include various types of skin hypersensitivity reactions. More serious reactions are listed as rare, particularly significant gastrointestinal bleeding and the potential for ulcers that may lead to perforation, as documented in regulatory safety texts.

Safety data highlights specific risks across different organ systems, including the Gastrointestinal, Blood and Lymphatic, and Immune systems. Serious adverse reactions cited in regulatory documents include cerebral bleeding and Reye's syndrome, a very rare but life-threatening condition associated with ASA use in children and adolescents who have viral infections accompanied by fever. The inhibitory effect on platelet aggregation persists for several days after cessation.

Population-specific safety constraints are explicitly defined. The medication is constrained for use during the third trimester of pregnancy and is contraindicated for children and adolescents with a viral illness. Furthermore, regulatory documents cite the risk of chronic kidney damage (analgesic nephropathy) as being associated with long-term use of analgesic products containing ASA.

Overdose and Emergency Response

Overdose and When to Seek Help

Any suspected overdose of this medicine requires immediate medical attention and contact with emergency services. Hospital admission is mandated for individuals who have ingested a potentially toxic dose, as continuous observation and supportive care are required. Acute toxicity is officially associated with an ingestion of a total dose ge 150 mg/kg of Acetylsalicylic Acid (ASA).

The manifestations of overdose are formally documented and can range from early signs such as Tinnitus (ringing in the ears), Nausea, Vomiting, Sweating, and Hyperventilation. These presentations may escalate to severe, life-threatening outcomes, including Convulsions, profound Metabolic Acidosis, Non-cardiogenic Pulmonary Oedema, and potential Coma. The acid-base status is a critical indicator, often progressing from respiratory alkalosis to a dominant metabolic acidosis.

The regulatory profile explicitly states that no specific antidote is known for ASA toxicity. Management focuses on supporting physiological stability and enhancing elimination through procedures such as Alkaline Diuresis or Hemodialysis in severe cases. Continuous monitoring of Serum Salicylate Levels, acid-base status, and electrolytes is a required component of hospital care. Pediatric patients and the elderly are officially noted as populations potentially facing more severe or atypical overdose presentations.

Therapeutic Uses of Upsarin C

What Upsarin C Treats: Main Uses and Benefits

Upsarin C is used to provide short-term symptomatic support across key therapeutic domains involving acute physical discomfort. The combination is commonly used to help with symptoms that create noticeable physiological strain. The main active component is commonly used to help with relieving pain and reducing a high temperature.

The medication is applied in addressing symptoms related to physical discomfort, such as mild to moderate headache, toothache, and musculoskeletal aches (myalgia and arthralgia). Furthermore, it is relevant for managing symptoms related to systemic imbalance, including elevated body temperature (fever). It is commonly used across conditions presenting with systemic or localized discomfort.

It may assist with maintaining functional stability when symptoms interfere with routine activities, providing supportive relief during acute symptomatic episodes. The inclusion of Ascorbic Acid (Vitamin C) may be part of supportive therapeutic management applied across domains where additional symptomatic support is needed. This combination contributes to easing the overall symptom load during periods of heightened symptoms.

Quick Fact: Focus on Acute Symptom Management	Description
Symptom Focus	Mild to moderate pain and fever.
Typical Context	Symptomatic support during seasonal illnesses or episodic aches.
Patient Benefit	Contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The eligibility profile for Upsarin C (Acetylsalicylic Acid/Ascorbic Acid) is defined by regulatory authorities through specific population criteria, contraindications, and cautionary use restrictions.

Eligibility Status	Applicable Population/Condition
Allowed Use	Adults for symptomatic relief. Children/Adolescents from 6 years (20 kg) or 12 years (40 kg) depending on regional label, but restricted in case of fever.
Contraindicated	Patients with hypersensitivity to ASA or NSAIDs, active gastrointestinal ulcers, haemorrhagic diathesis, or severe renal, hepatic, or uncontrolled cardiac insufficiency.
Contraindicated	Use during the last trimester of pregnancy (after 24 weeks). Concomitant treatment with Methotrexate at doses ge 15 mg/week.
Conditional Use	Patients with non-severe renal or hepatic impairment, glucose-6-phosphate dehydrogenase (G6PD) deficiency, or those prone to gout [Subra BG].
Not Recommended	Children and adolescents with feverish illnesses unless medically advised, due to the specific risk of Reye's syndrome.

Eligibility is also constrained by the Ascorbic Acid component, which contraindicates use in patients with oxalate-urolithiasis (kidney stones) and iron storage diseases [Subra BG]. Use during the first and second trimesters of pregnancy is restricted to cases of necessity at the lowest possible dose, and high-dose or prolonged use during lactation is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Upsarin C is primarily defined by its main active component, Acetylsalicylic Acid (ASA), and to a lesser extent, Ascorbic Acid (Vitamin C), as officially documented in regulatory labels.

Contraindicated Combinations and Major Risks

Co-administration with Methotrexate (ge 15 mg/week) is a prohibited combination due to the officially documented risk of increased Methotrexate toxicity related to decreased renal clearance. The ASA component increases the risk of haemorrhage when co-administered with Oral Anticoagulants (e.g., Warfarin) and other Inhibitors of Platelet Aggregation.

Pharmacodynamic and Pharmacokinetic Interactions

Interacting Substance	Official Interaction Outcome (Regulatory Wording)
Other NSAIDs	Increased risk of gastrointestinal ulcers and haemorrhage.
Digoxin	Increased plasma concentration.
Diuretics, ACE Inhibitors, ARBs	Reduction of antihypertensive effect.
Amphetamine	Decreased serum levels (Ascorbic Acid component via urine acidification).
Uricosuric Agents (e.g., Probenecid)	Reduction in the uricosuric effect due to competition for renal elimination pathways.
Iron	Ascorbic acid increases the absorption of iron.

Substance and Population-Specific Cautions

Alcohol co-administration is associated with an increased risk of gastrointestinal bleeding and ulcers. Oral Contraceptives and smoking are documented to decrease the plasma concentration of Ascorbate. The risk of haemorrhage when combined with high-dose Heparins is officially noted to be increased in elderly patients (ge 65 years) and those with renal impairment.

Mechanism of Action

How Upsarin C Works

Irreversible Blockade of Prostaglandin Synthesis

The primary mechanism involves Acetylsalicylic Acid (ASA) acting as an acetylating agent to permanently deactivate the Cyclooxygenase (COX) enzymes (COX-1 and COX-2). This molecular action stops the conversion of arachidonic acid into prostanoids ( PGE2 being critical), fundamentally disrupting the eicosanoid synthesis pathway. The consequence is the physiological modulation of processes mediated by these molecular signals.

Modulation of Central Thermoregulation and Nociception

ASA's action influences two key physiological systems: Central Thermoregulation in the hypothalamus and Peripheral Nociceptive Signaling. By reducing PGE2 concentrations in the brain, the mechanism allows the body's thermostatic set-point to reset, which leads to increased heat dissipation. Concurrently, the reduction of prostanoids at injury sites elevates the threshold of peripheral nerve sensitization, thereby reducing the overall signal transmission of nociceptive impulses.

Component-Specific Mechanistic Support

The Ascorbic Acid component (delivered as Sodium Ascorbate) does not participate in the COX cascade but acts as a buffering agent in the effervescent solution, which optimizes the solution's pH to facilitate the rapid dissolution of ASA. This physical mechanism facilitates a rapid presentation of the active ingredient for absorption, working alongside the core enzyme inhibition.

Dosage and Administration Information

Upsarin C is intended for oral administration as a solution following preparation. The effervescent tablet is designed to be dissolved completely in a glass of water before it is consumed, aligning with specific preparation requirements. This medicine is typically intended for use after main meals or on a full stomach, a condition specified to guide proper intake.

The standard single dose for adults and adolescents over 15 years is typically defined as one to two effervescent tablets (330 mg to 660 mg Acetylsalicylic Acid). The instructions specify that this single dose must not be repeated until a minimum interval of four hours has passed. Adherence to this frequency pattern is essential. Furthermore, the instructions specify a strict maximum daily dose that should not be exceeded, commonly limited to six tablets (1980 mg ASA) over a 24-hour period.

Guidance establishes that Upsarin C is designated for short-term use. The established duration of self-treatment is often restricted to three days for fever or three to four days for pain relief, beyond which medical consultation is necessary. Use is generally reserved for individuals 15 years of age or older; however, specific dosing may be determined by body weight in some regional guidelines. These administration principles define the scope of the medicine's proper use.

Recent Clinical Evidence

Upsarin C: Recent Clinical Evidence

Research Evidence Overview and Scope

The clinical evidence for Upsarin C incorporates research on its main component, Acetylsalicylic Acid (ASA), which has been studied for outcomes related to physical discomfort. This section summarizes the research that has been explored, detailing the types of studies that exist and the aspects that remain uncertain. The research examined is relevant in trials assessing short-term or episodic symptom patterns.

Evidence for Symptomatic Relief of Acute Pain

Research has explored the use of the medicine’s components for the short-term relief of acute pain, a condition marked by functional limitations. Short-term Randomized Controlled Trials (RCTs) and comparative studies of the active ingredient, ASA, were evaluated in cohorts with conditions associated with acute or disruptive episodes, such as headache. The research examined patient-reported outcomes describing perceived discomfort, focusing on outcomes related to physical discomfort that include those measured in studies for headaches and muscle aches. Studies report how symptoms evolved in the observed populations, with findings describing patterns observed in the studies related to pain measurements. Research highlights that for the core component, patterns of symptom change were reported in the study populations. While the core ASA component was studied for analgesic effects, the specific clinical contribution of Ascorbic Acid to that action is not extensively characterized, and long-term effects are not fully established.

Research on the Effervescent Formulation and Speed of Action

Specific clinical studies have been applied in research contexts to understand the characteristics of the effervescent formulation used in Upsarin C. Studies reported measurements where data show patterns related to the time taken for action to begin compared to conventional tablet forms.

Evidence for Management of Fever and Flu-like Symptoms

The medicine was studied for research contexts involving fluctuating or unstable symptoms, particularly those associated with common cold or flu-like conditions. Research describes patterns observed in the studies related to temperature reduction and the evolution of general cold and flu symptoms in the observed populations. Evidence suggests that the studies focused on temporary physiological imbalance associated with these acute episodes.

What is Still Uncertain About the Research Evidence

Subgroup findings are not fully established, and data for certain groups (e.g., those with specific chronic conditions) remain insufficient. Comparative evidence regarding the specific formulation is limited. Overall, evidence is limited regarding the distinct, added clinical value of the Ascorbic Acid component. Research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Upsarin C (FAQ)

Q: Is Upsarin C the same as regular aspirin, just with Vitamin C added?

Upsarin C is officially a fixed-dose combination of Acetylsalicylic Acid (ASA) and Ascorbic Acid (Vitamin C). The key distinction is that it is formulated as an effervescent tablet, with official instructions requiring it to be dissolved in water before ingestion. This preparation facilitates faster dissolution and subsequent absorption of the active ingredient compared to conventional solid tablets.

Q: Does Upsarin C work immediately after I take it?

Studies and official information indicate that the effervescent formulation is absorbed more quickly than a standard tablet. This design facilitates a rapid presentation of the active ingredient to the body, which is studied in relation to the speed of symptomatic relief for conditions like pain or fever.

Q: Does Upsarin C cause drowsiness or affect my ability to drive?

Official safety data for Acetylsalicylic Acid does not commonly list drowsiness as a primary side effect. However, if any side effects such as dizziness or vertigo are reported, activities requiring mental alertness, such as driving or operating machinery, may be affected.

Q: What happens if I accidentally take Upsarin C with an antacid?

Regulatory documents note a potential interaction involving the Ascorbic Acid component. If taken with aluminum-containing antacids, Ascorbic Acid may increase the absorption of aluminum, potentially leading to increased side effects from the antacid component.

Q: Can I use Upsarin C if I am currently taking blood-thinning medication?

Use of this medicine is contraindicated with oral anticoagulants. Furthermore, combining it with other medicines that inhibit platelet aggregation or blood clotting agents, such as Heparin, is associated with an increased risk of bleeding, especially for older adults or those with renal impairment.

Q: Why is Upsarin C often dissolved in water instead of swallowed whole?

The medicine is provided as an effervescent tablet, and regulatory instructions mandate that it must be dissolved completely in a glass of water before use. This process facilitates rapid dissolution and absorption of the active ingredient, which is a characteristic studied in its speed of action.

Q: Are there any common foods or drinks that should be avoided when using Upsarin C?

Official warnings specifically state that the co-administration of alcohol is associated with an increased risk of gastrointestinal bleeding and ulcers. Beyond this, the medicine is typically intended to be taken after main meals.

Q: Can Upsarin C be used by people who are trying to manage their blood pressure?

Official documents indicate that the Acetylsalicylic Acid component may reduce the antihypertensive effect of certain blood pressure medications, including Diuretics, ACE Inhibitors, and Angiotensin II Receptor Blockers (ARBs). Information regarding the compatibility of Upsarin C with other medications is available in the 'Interactions' section.

Q: Why is there a warning about using Upsarin C before surgery?

The warning is associated with the active ingredient's inhibitory effect on platelet aggregation (the ability of blood to clot), which persists for several days after treatment is stopped. This effect can increase the risk of bleeding during or after a surgical or dental procedure.

Q: Is Upsarin C generally considered suitable for older adults?

The medicine's use in older adults is subject to specific caution. Regulatory documents cite an increased risk of haemorrhage when combined with high-dose Heparins in patients aged 65 years or older.

Q: Does Upsarin C affect the results of any common medical tests?

Official documents indicate that the Ascorbic Acid component can potentially interfere with the results of certain laboratory tests. This includes tests for urine glucose and specific blood coagulation tests.

Q: Why is it important to check the expiration date on Upsarin C?

The expiration date is directly linked to the medicine's official shelf life. This date defines the period during which the product's stability, potency, and quality are guaranteed, provided the required storage instructions (such as protecting from moisture and light) are met.

Q: If I take other vitamin supplements, can I still take Upsarin C?

Regulatory documents list that the Ascorbic Acid component can increase the absorption of iron. Furthermore, official information notes that oral contraceptives and smoking are documented to decrease the plasma concentration of Ascorbate. For detailed guidance on specific supplements, consult the medicine's official interactions documentation.

Q: How quickly should I expect to feel better after taking Upsarin C for a fever?

Clinical research shows that the effect of the active ingredient on temperature reduction is one of the studied outcomes. Due to its effervescent formulation, the medicine is designed for rapid absorption, which is characteristic of a fast onset of symptomatic relief.

Q: Does Upsarin C contain any gluten or common allergens?

The official list of ingredients and excipients (inactive components) is detailed in regulatory documents and outlines all components of the tablet. Regulatory guidelines mandate that all excipients, including potential allergens or additives, are noted in this official documentation.

Q: Is the effervescent (fizzy) form of Upsarin C absorbed faster than a tablet?

Specific clinical studies have been applied in research contexts to understand the characteristics of the effervescent formulation. Data from these studies show patterns related to faster absorption compared to conventional solid tablets.

Q: Does Upsarin C contain caffeine or other stimulants?

The official list of active ingredients is Acetylsalicylic Acid and Sodium Ascorbate (Ascorbic Acid). Caffeine or other stimulants are not listed as active components in the medicine's regulatory composition.

How should Upsarin C be stored and disposed of?

The official storage and disposal guidelines for Upsarin C are defined by regulatory authorities to maintain the product's stability and ensure environmental safety.

Storage Requirements

The medicine must be stored below 25 C. As an effervescent formulation, it is mandatory to protect the tablets from moisture and light. This is achieved by storing the product in the original tube packaging and ensuring the tube is kept tightly closed at all times. All units must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Upsarin C must not be disposed of via wastewater or placed in household waste. The correct procedure is to ask a pharmacist for advice on how to properly discard the medicine according to local pharmaceutical waste regulations.

Upsarin C